Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice
A Ram Hong (Hong AR), Bo Kyung Koo (Koo BK), Sang Wan Kim (Kim SW), Ka Hee Yi (Yi KH), Min Kyong Moon (Moon MK)
Diabetes Metab J. 2019;43(5):590-606.   Published online 2019 Feb 28     DOI: https://doi.org/10.4093/dmj.2018.0134
Citations to this article as recorded by Crossref logo
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
Irish Journal of Medical Science (1971 -).2022; 191(4): 1647.     CrossRef
Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
Nauman Wazir, Shafqat Ur Rehman
Journal of Gandhara Medical and Dental Science.2022; 9(1): 24.     CrossRef
Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd. Wasem Alsabbagh, John‐Michael Gamble
Diabetic Medicine.2022;[Epub]     CrossRef
Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus
Bipin Sethi, Subhankar Chowdhury, Supratik Bhattacharya, Sagar Katare, Sachin Suryawanshi, Hanmant Barkate
International Journal of Diabetes in Developing Countries.2022;[Epub]     CrossRef
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
Yonsei Medical Journal.2022; 63(9): 825.     CrossRef
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Ha Young Jang, In-Wha Kim, Jung Mi Oh
Frontiers in Pharmacology.2022;[Epub]     CrossRef
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Ai-Yu Yang, Hung-Chun Chen
International Journal of Clinical Pharmacy.2021; 43(4): 1015.     CrossRef
Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
Zhiqin Zhang, Lihua Ni, Lian Zhang, Dongqing Zha, Chun Hu, Lingli Zhang, Huiling Feng, Xiaobao Wei, Xiaoyan Wu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 227.     CrossRef
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
Hiroaki Seino
Diabetes Therapy.2021; 12(3): 863.     CrossRef
Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
Diabetes Care.2021; 44(10): 2419.     CrossRef
Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
Muhammad Afzal, Fahad Al-Abbasi, Muhammad Nadeem, Sultan Alshehri, Mohammed Ghoneim, Syed Imam, Waleed Almalki, Imran Kazmi
Metabolites.2021; 11(11): 794.     CrossRef
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Diabetes & Metabolism Journal.2020; 44(4): 489.     CrossRef
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Kidney Research and Clinical Practice.2020; 39(3): 269.     CrossRef
Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
Jung-Fu Chen, Yun-Shing Peng, Chung-Sen Chen, Chin-Hsiao Tseng, Pei-Chi Chen, Ting-I Lee, Yung-Chuan Lu, Yi-Sun Yang, Ching-Ling Lin, Yi-Jen Hung, Szu-Ta Chen, Chieh-Hsiang Lu, Chwen-Yi Yang, Ching-Chu Chen, Chun-Chuan Lee, Pi-Jung Hsiao, Ju-Ying Jiang, S
PeerJ.2020; 8: e9998.     CrossRef
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti
Journal of Diabetes Research.2019; 2019: 1.     CrossRef
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Ji A Seo
Diabetes & Metabolism Journal.2019; 43(5): 578.     CrossRef